Cargando…

Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence

BACKGROUND: As a transnational policy network, the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) aligns international regulatory standards to address the pressures of globalization on the pharmaceutical industry and increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiktorowicz, Mary, Moscou, Kathy, Lexchin, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106922/
https://www.ncbi.nlm.nih.gov/pubmed/30134929
http://dx.doi.org/10.1186/s12992-018-0402-5
_version_ 1783349872401842176
author Wiktorowicz, Mary
Moscou, Kathy
Lexchin, Joel
author_facet Wiktorowicz, Mary
Moscou, Kathy
Lexchin, Joel
author_sort Wiktorowicz, Mary
collection PubMed
description BACKGROUND: As a transnational policy network, the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) aligns international regulatory standards to address the pressures of globalization on the pharmaceutical industry and increase access to new medicines. Founding ICH members include regulators and pharmaceutical industry trade associations in the European Union, the United States and Japan. In this paper we explore the manner in which state interdependence fosters the conditions for regulatory harmonization by tracing the underlying parallels between ICH and member state pharmacogovernance to clarify emergent patterns in regulatory policy convergence. RESULTS: A shift to the life cycle approach to pharmaceutical regulation corresponded with international convergence in pre-market standards as emphasis shifted to post-market standards where convergence remains unresolved. Transnational pharmacogovernance was found to concentrate regulatory authority within a co-regulatory model of bilateral negotiation with pharmaceutical trade associations in defining safety and efficacy standards. Given a context of state interdependence, parallels were found between transnational and ICH member pharmacogovernance modes that guide policy development. Divergent modes of state regulatory governance that re-calibrate perceptions of risk and risk mitigation were found to coincide with post-market policy dissonance. CONCLUSION: Although interdependence fostered harmonization in pre-market standards and aligned with increased focus on post-market approaches, the confluence of divergent state governance modes and perceptions of risk may inspire improvisation in post-market standards. As the ICH expands to an ensemble with a greater global reach, further research is needed to clarify the manner in which interdependence shapes transnational pharmacogovernance and the conditions that foster policy convergence in the public interest. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12992-018-0402-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6106922
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61069222018-08-29 Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence Wiktorowicz, Mary Moscou, Kathy Lexchin, Joel Global Health Research BACKGROUND: As a transnational policy network, the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) aligns international regulatory standards to address the pressures of globalization on the pharmaceutical industry and increase access to new medicines. Founding ICH members include regulators and pharmaceutical industry trade associations in the European Union, the United States and Japan. In this paper we explore the manner in which state interdependence fosters the conditions for regulatory harmonization by tracing the underlying parallels between ICH and member state pharmacogovernance to clarify emergent patterns in regulatory policy convergence. RESULTS: A shift to the life cycle approach to pharmaceutical regulation corresponded with international convergence in pre-market standards as emphasis shifted to post-market standards where convergence remains unresolved. Transnational pharmacogovernance was found to concentrate regulatory authority within a co-regulatory model of bilateral negotiation with pharmaceutical trade associations in defining safety and efficacy standards. Given a context of state interdependence, parallels were found between transnational and ICH member pharmacogovernance modes that guide policy development. Divergent modes of state regulatory governance that re-calibrate perceptions of risk and risk mitigation were found to coincide with post-market policy dissonance. CONCLUSION: Although interdependence fostered harmonization in pre-market standards and aligned with increased focus on post-market approaches, the confluence of divergent state governance modes and perceptions of risk may inspire improvisation in post-market standards. As the ICH expands to an ensemble with a greater global reach, further research is needed to clarify the manner in which interdependence shapes transnational pharmacogovernance and the conditions that foster policy convergence in the public interest. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12992-018-0402-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-08-22 /pmc/articles/PMC6106922/ /pubmed/30134929 http://dx.doi.org/10.1186/s12992-018-0402-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wiktorowicz, Mary
Moscou, Kathy
Lexchin, Joel
Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence
title Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence
title_full Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence
title_fullStr Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence
title_full_unstemmed Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence
title_short Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence
title_sort transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106922/
https://www.ncbi.nlm.nih.gov/pubmed/30134929
http://dx.doi.org/10.1186/s12992-018-0402-5
work_keys_str_mv AT wiktorowiczmary transnationalpharmacogovernanceemergentpatternsinthejazzofpharmaceuticalpolicyconvergence
AT moscoukathy transnationalpharmacogovernanceemergentpatternsinthejazzofpharmaceuticalpolicyconvergence
AT lexchinjoel transnationalpharmacogovernanceemergentpatternsinthejazzofpharmaceuticalpolicyconvergence